Business Context and Reporting Period
This Form 8-K, dated September 1, 2026, reports the consummation of a merger between Crinetics Pharmaceuticals, Inc. (the "Company") and Vertex Pharmaceuticals Incorporated ("Parent"). On the Closing Date, Clark Merger Sub, Inc. merged with and into the Company, which continues as a wholly owned subsidiary of Vertex. The Company's common stock was delisted from the Nasdaq Global Select Market, and its reporting obligations under the Exchange Act were terminated.
Key Financial Metrics
- Merger Consideration: $85.00 per share in cash for each outstanding share of Company Common Stock.
- Total Transaction Value: Approximately $10.0 billion in aggregate consideration paid by Parent.
- Funding Source: A combination of cash on hand and borrowings under Parent's term loan credit agreement.
- Equity Compensation: All unvested stock options and restricted stock units (RSUs) became fully vested immediately prior to the Effective Time. In-the-money options were cashed out at the excess of the Merger Consideration over the exercise price; out-of-the-money options were canceled for no consideration.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific revenue, profit, cash flow, margin, or debt figures for the Company as of the reporting date.
Material Changes Versus Prior Period
- Change in Control: The Company transitioned from a publicly traded independent entity to a wholly owned subsidiary of Vertex Pharmaceuticals.
- Termination of Agreements: The Company terminated its 2018 Employee Stock Purchase Plan, the Sales Agreement with SVB Leerink LLC and Cantor Fitzgerald & Co., and its 2018, 2015, and 2021 equity incentive plans.
- Corporate Governance: All incumbent directors and officers resigned or were removed. Charles Wagner became the sole director, and new officers (Charles Wagner, Prasanna Thombre, and Omar White) were appointed to the Surviving Corporation.
- Listing Status: Trading in Company Common Stock was suspended, and the stock was removed from listing and registration on Nasdaq.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or management commentary regarding future operations, as the Company is now a subsidiary of Vertex. The primary risk disclosed is the cessation of the Company's independent existence and the termination of its registration under Section 12(b) and 12(g) of the Exchange Act. There are no known arrangements that may result in a further change of control subsequent to this transaction.
Important Facts for Investor Verification
- Verify the final cash payout of $85.00 per share received by shareholders.
- Confirm the cash-out value for vested and unvested equity awards based on the $85.00 strike price differential.
- Review the full text of the Merger Agreement (Exhibit 2.1) for details on funding and conditions.
- Confirm the effective date of the delisting and the termination of the Company's SEC reporting obligations.